BASF ups Pronova bid


BASF has increased its offer for Norwegian firm Pronova BioPharma, which specialises in omega-3 fatty acids, from €664 million (£530 million) to €684 million in an attempt to win over reluctant shareholders.

The company made its initial offer in November 2012 with the support of the board and shareholders representing 60% of the company, including private equity fund Herkules, which owns a 50% stake.

Since then, the bid has been accepted by investors owning 70% of the issued shares. The new offer lasts until 18 January and will not be extended, BASF says.

Pronova makes active pharmaceutical ingredients based on omega-3 fatty acids that are used to treat cardiovascular conditions. It also makes dietary supplements. It employs 300 people and makes annual sales of about NOK1.7 billion (£180 million).

BASF strengthened its position in this growing market in May 2012 when it bought UK firm Equateq.


Related Content

BASF bids €664m for omega-3 company

22 November 2012 Business

news image

Pronova BioPharma makes pharmaceutical ingredients as well as nutritional supplements based in omega-3 fatty acids

BASF to cut 260 jobs in nutrition and health

1 May 2014 Business

news image

Firm to sell Norwegian site and shift focus towards Asia

Most Read

Quintuple bond activates small stable molecules

19 September 2014 Research

news image

Exotic complexes suggest route to synthetic feedstock

Computer simulations point to formamide as prebiotic intermediate in ‘Miller’ mixtures

16 September 2014 News and Analysis

news image

Electric field may have provided more than just energy for primordial chemistry

Most Commented

US genomics lead being lost to China

17 September 2014 News and Analysis

news image

NIH senior leaders are sounding the alarm bells, saying the US's pre-eminence in genomics research is under threat

The trouble with boycotts

29 August 2014 Critical Point

news image

Cutting academic ties with a censured state can do more harm than good, says Mark Peplow